• Werewolf Therapeutics reported cancer trial results presented at the Society for Immunotherapy of Cancer’s annual meeting on November 7, 2026.
• WTX-124 showed durable tumor responses as monotherapy or with pembrolizumab in previously treated patients with advanced solid tumors.
• The FDA aligned with the recommended Phase 2 dose for WTX-124, which was administered safely in outpatient settings.
• WTX-330 was well tolerated with an optimized formulation, showing tumor shrinkage in patients with advanced, treatment-resistant cancers.
• Neither drug showed evidence of vascular leak syndrome or recurrence of prior immune-related adverse events, supporting potential further development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090830PRIMZONEFULLFEED9873224) on November 09, 2026, and is solely responsible for the information contained therein.